Puretech announces completion of enrollment in phase 2b elevate ipf trial of lyt-100 (deupirfenidone) in idiopathic pulmonary fibrosis

Boston--(business wire)--puretech announces completion of enrollment in phase 2b elevate ipf trial of lyt-100 (deupirfenidone) in idiopathic pulmonary fibrosis.

PRTC Ratings Summary

PRTC Quant Ranking